| Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia IE Ahn, C Underbayev, A Albitar, SEM Herman, X Tian, I Maric, DC Arthur, ... Blood, The Journal of the American Society of Hematology 129 (11), 1469-1479, 2017 | 375 | 2017 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 324 | 2020 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ... Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018 | 222 | 2018 |
| Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib I Ahn, T Jerussi, M Farooqui, M Tian, A Wiestner, J Gea-Banacloche Blood 128 (15), 1940-1943, 2016 | 182 | 2016 |
| Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines C Pleyer, MA Ali, JI Cohen, X Tian, S Soto, IE Ahn, EM Gaglione, ... Blood, The Journal of the American Society of Hematology 137 (2), 185-189, 2021 | 132 | 2021 |
| Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations IE Ahn, X Tian, A Wiestner New England Journal of Medicine 383 (5), 498-500, 2020 | 129 | 2020 |
| A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era HR Robinson, J Qi, EM Cook, C Nichols, EL Dadashian, C Underbayev, ... Blood, The Journal of the American Society of Hematology 132 (5), 521-532, 2018 | 113 | 2018 |
| Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model IE Ahn, X Tian, D Ipe, M Cheng, M Albitar, LC Tsao, L Zhang, W Ma, ... Journal of Clinical Oncology 39 (6), 576-585, 2021 | 105 | 2021 |
| Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib C Sun, P Nierman, EK Kendall, J Cheung, M Gulrajani, SEM Herman, ... Blood, The Journal of the American Society of Hematology 136 (1), 93-105, 2020 | 101 | 2020 |
| Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia E Tissino, D Benedetti, SEM Herman, E Ten Hacken, IE Ahn, KG Chaffee, ... Journal of experimental medicine 215 (2), 681-697, 2018 | 93 | 2018 |
| Temporal differential effects of proinflammatory cytokines on osteoclastogenesis SJ Moon, IE Ahn, H Jung, H Yi, J Kim, Y Kim, SK Kwok, KS Park, JK Min, ... International journal of molecular medicine 31 (4), 769-777, 2013 | 86 | 2013 |
| Targeting Bruton’s tyrosine kinase in CLL IE Ahn, JR Brown Frontiers in immunology 12, 687458, 2021 | 74 | 2021 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 66 | 2021 |
| Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials JN Allan, T Shanafelt, A Wiestner, C Moreno, SM O’Brien, J Li, G Krigsfeld, ... British Journal of Haematology 196 (4), 947-953, 2022 | 58 | 2022 |
| Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib C Vitale, IE Ahn, M Sivina, A Ferrajoli, WG Wierda, Z Estrov, SN Konoplev, ... Haematologica 101 (6), e254, 2016 | 51 | 2016 |
| Overcoming acquired epigenetic resistance to BTK inhibitors AL Shaffer III, JD Phelan, JQ Wang, DW Huang, GW Wright, M Kasbekar, ... Blood cancer discovery 2 (6), 630-647, 2021 | 46 | 2021 |
| Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib C Brieghel, K Aarup, MH Torp, MA Andersen, CW Yde, X Tian, A Wiestner, ... Clinical Cancer Research 27 (16), 4531-4538, 2021 | 36 | 2021 |
| Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL IE Ahn, N Basumallik, X Tian, S Soto, A Wiestner Blood, The Journal of the American Society of Hematology 133 (22), 2452-2455, 2019 | 34 | 2019 |
| Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with … A Albitar, W Ma, I DeDios, J Estella, I Ahn, M Farooqui, A Wiestner, ... Oncotarget 8 (11), 17936, 2017 | 33 | 2017 |
| Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high … CE Ryan, BL Lampson, S Tyekucheva, LR Hackett, Y Ren, SJ Shupe, ... Blood 140 (Supplement 1), 837-838, 2022 | 32 | 2022 |
